Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages.

Triantafyllopoulou A, Franzke CW, Seshan SV, Perino G, Kalliolias GD, Ramanujam M, van Rooijen N, Davidson A, Ivashkiv LB.

Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3012-7. doi: 10.1073/pnas.0914902107. Epub 2010 Jan 26.

2.

A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis.

Bethunaickan R, Berthier CC, Ramanujam M, Sahu R, Zhang W, Sun Y, Bottinger EP, Ivashkiv L, Kretzler M, Davidson A.

J Immunol. 2011 Apr 15;186(8):4994-5003. doi: 10.4049/jimmunol.1003010. Epub 2011 Mar 16.

3.

Interleukin 17 signaling drives Type I Interferon induced proliferative crescentic glomerulonephritis in lupus-prone mice.

Ramani K, Biswas PS.

Clin Immunol. 2016 Jan;162:31-6. doi: 10.1016/j.clim.2015.10.009. Epub 2015 Nov 10.

PMID:
26556529
4.

Macrophage depletion ameliorates nephritis induced by pathogenic antibodies.

Chalmers SA, Chitu V, Herlitz LC, Sahu R, Stanley ER, Putterman C.

J Autoimmun. 2015 Feb;57:42-52. doi: 10.1016/j.jaut.2014.11.007. Epub 2014 Dec 29.

5.

Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis.

Schiffer L, Bethunaickan R, Ramanujam M, Huang W, Schiffer M, Tao H, Madaio MP, Bottinger EP, Davidson A.

J Immunol. 2008 Feb 1;180(3):1938-47. Erratum in: J Immunol. 2008 Mar 1;180(5):3613. Madaio, Michael M [corrected to Madaio, Michael P].

7.

Anti-tumor necrosis factor α treatment of interferon-α-induced murine lupus nephritis reduces the renal macrophage response but does not alter glomerular immune complex formation.

Bethunaickan R, Sahu R, Liu Z, Tang YT, Huang W, Edegbe O, Tao H, Ramanujam M, Madaio MP, Davidson A.

Arthritis Rheum. 2012 Oct;64(10):3399-408. doi: 10.1002/art.34553.

8.

Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.

Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, Galle PR, Schwarting A.

J Rheumatol. 2010 Jan;37(1):60-70. doi: 10.3899/jrheum.090194. Epub 2009 Dec 1.

PMID:
19955044
9.

The role of aldosterone blockade in murine lupus nephritis.

Monrad SU, Killen PD, Anderson MR, Bradke A, Kaplan MJ.

Arthritis Res Ther. 2008;10(1):R5. doi: 10.1186/ar2353. Epub 2008 Jan 15.

10.

Dependence of Glomerulonephritis Induction on Novel Intraglomerular Alternatively Activated Bone Marrow-Derived Macrophages and Mac-1 and PD-L1 in Lupus-Prone NZM2328 Mice.

Sung SJ, Ge Y, Dai C, Wang H, Fu SM, Sharma R, Hahn YS, Yu J, Le TH, Okusa MD, Bolton WK, Lawler JR.

J Immunol. 2017 Apr 1;198(7):2589-2601. doi: 10.4049/jimmunol.1601565. Epub 2017 Feb 20.

PMID:
28219886
11.
12.

Endogenous interleukin (IL)-17A promotes pristane-induced systemic autoimmunity and lupus nephritis induced by pristane.

Summers SA, Odobasic D, Khouri MB, Steinmetz OM, Yang Y, Holdsworth SR, Kitching AR.

Clin Exp Immunol. 2014 Jun;176(3):341-50. doi: 10.1111/cei.12287.

13.

Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells.

Lourenço EV, Wong M, Hahn BH, Palma-Diaz MF, Skaggs BJ.

Arthritis Rheumatol. 2014 Mar;66(3):674-85. doi: 10.1002/art.38259.

14.

Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells.

Patole PS, Gröne HJ, Segerer S, Ciubar R, Belemezova E, Henger A, Kretzler M, Schlöndorff D, Anders HJ.

J Am Soc Nephrol. 2005 May;16(5):1326-38. Epub 2005 Mar 16.

15.

Function of the Th17/interleukin-17A immune response in murine lupus nephritis.

Schmidt T, Paust HJ, Krebs CF, Turner JE, Kaffke A, Bennstein SB, Koyro T, Peters A, Velden J, Hünemörder S, Haag F, Steinmetz OM, Mittrücker HW, Stahl RA, Panzer U.

Arthritis Rheumatol. 2015 Feb;67(2):475-87. doi: 10.1002/art.38955.

16.

Renal platelet-derived growth factor gene expression in NZB/W F1 mice with lupus and ddY mice with IgA nephropathy.

Nakamura T, Ebihara I, Nagaoka I, Tomino Y, Koide H.

Clin Immunol Immunopathol. 1992 May;63(2):173-81.

PMID:
1611719
17.

Predominance of Th1 immune response in diffuse proliferative lupus nephritis.

Masutani K, Akahoshi M, Tsuruya K, Tokumoto M, Ninomiya T, Kohsaka T, Fukuda K, Kanai H, Nakashima H, Otsuka T, Hirakata H.

Arthritis Rheum. 2001 Sep;44(9):2097-106.

18.

Toll-like receptor 2 is required for autoantibody production and development of renal disease in pristane-induced lupus.

Urbonaviciute V, Starke C, Pirschel W, Pohle S, Frey S, Daniel C, Amann K, Schett G, Herrmann M, Voll RE.

Arthritis Rheum. 2013 Jun;65(6):1612-23. doi: 10.1002/art.37914.

19.

Mediators of inflammation and their effect on resident renal cells: implications in lupus nephritis.

Yung S, Cheung KF, Zhang Q, Chan TM.

Clin Dev Immunol. 2013;2013:317682. doi: 10.1155/2013/317682. Epub 2013 Sep 22. Review.

20.

Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis.

Faust J, Menke J, Kriegsmann J, Kelley VR, Mayet WJ, Galle PR, Schwarting A.

Arthritis Rheum. 2002 Nov;46(11):3083-95.

Supplemental Content

Support Center